Phyllis C. Zee, MD, PhD

Expert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.

Key opinion leaders consider the impact of the COVID-19 pandemic on the diagnosis and treatment of narcolepsy and comment on improvements in symptom management at home.

Experts in neurology review the recent approvals of pitolisant and solriamfetol for the management of excessive daytime sleepiness (EDS) and compare their mechanisms of action.

Key opinion leaders discuss pharmacotherapeutic options for the management of narcolepsy symptoms and examine the safety and efficacy of potential treatments.

Experts in neurology discuss the goals of treatment and consider behavioral approaches to the management of narcolepsy and idiopathic hypersomnia including naps and exposure to sunlight.

Key opinion leaders review reasons for diagnostic delay in narcolepsy including medical and psychiatric comorbidities and discuss diagnostic tools such as sleep diaries, polysomnograms, and cerebrospinal fluid testing.

Expert neurologists discuss the pathophysiology of narcolepsy and examine the role of genetic predisposition, environmental triggers, and immune system involvement.

Key opinion leaders discuss symptoms associated with narcolepsy such as cataplexy, hallucinations, sleep paralysis, and excessive daytime sleepiness (EDS).

Experts in the management of sleep disorders provide an overview of excessive daytime sleepiness (EDS) including potential causes and consequences.

The director of the center for circadian and sleep medicine at Northwestern University spoke about the importance of recognizing insomnia as a clinical diagnosis since it affects patients 24-hours a day, not just during sleep.